Sandoz Strikes Shionogi Partnership as Part of Pain Play
By securing commercial rights to Shionogi’s Rizmoic drug for opioid-induced constipation, Sandoz is seeking to broaden its European pain treatments portfolio.
You may also be interested in...
Sandoz is to pay up to €400m for Aspen’s anesthetics and other specialty off-patent brands in Japan, strengthening the Novartis division’s local position in the hospitals market.
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.